| Date Filed | Type | Description |
| 02/16/2021 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 0% stake in Immunomedics, Inc. |
| 11/09/2020 |
SC 13G/A
| BlackRock Inc. reports a 0% stake in IMMUNOMEDICS INC |
| 11/02/2020 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 10/30/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/30/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/30/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/23/2020 |
SC 13D/A
| venBio Select Advisor LLC reports a 0% stake in Immunomedics, Inc. |
| 10/23/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/23/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/23/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/23/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/23/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/23/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/23/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/23/2020 |
8-K
| Resignation/termination of a director |
| 10/23/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 10/23/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/23/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/14/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/14/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/13/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/13/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/12/2020 |
GN
| Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma |
| 10/02/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/02/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 09/25/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 09/25/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 09/24/2020 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 09/24/2020 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 09/24/2020 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 09/22/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IMMU, VRTU, RST, and CBMG Buyouts |
| 09/21/2020 |
8-K
| Quarterly results |
| 09/19/2020 |
GN
| Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer |
| 09/19/2020 |
GN
| Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer |
|